Ex-Metacrine chief Pre­ston Klassen recharges at mi­croR­NA biotech; Al­lo­gene be­gins search for a CFO

Pre­ston Klassen has mapped out his next des­ti­na­tion as pres­i­dent and R&D chief of mi­croR­NA de­vel­op­er Reg­u­lus Ther­a­peu­tics. Klassen was the CEO of Metacrine, a biotech co-found­ed and chaired by Rich Hey­man that was en­snarled in tox­i­c­i­ty is­sues with its NASH pro­gram. Metacrine would hand out pink slips to half its work­force be­fore a merg­er with Equi­l­li­um that ul­ti­mate­ly didn’t ma­te­ri­al­ize. Ear­li­er, Klassen was CMO and US pres­i­dent of San­i­fit and then led R&D at Are­na Phar­ma­ceu­ti­cals. Reg­u­lus al­so wel­comed Al­ler­gan vet Cur­tis Mon­nig as VP of CMC, the same po­si­tion he pre­vi­ous­ly held at Jan­u­ary Ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.